|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dai X, Xiang L, Li T and Bai Z: Cancer
hallmarks, biomarkers and breast cancer molecular subtypes. J
Cancer. 7:1281–1294. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cianfrocca M and Gradishar W: New
molecular classifications of breast cancer. CA Cancer J Clin.
59:303–313. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gralow JR, Burstein HJ, Wood W, Hortobagyi
GN, Gianni L, von Minckwitz G, Buzdar AU, Smith IE, Symmans WF,
Singh B and Winer EP: Preoperative therapy in invasive breast
cancer: Pathologic assessment and systemic therapy issues in
operable disease. J Clin Oncol. 26:814–819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic subtypes. J Clin Oncol. 30:1796–1804. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cortazar P, Zhang L, Untch M, Mehta K,
Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L,
Valagussa P, et al: Pathological complete response and long-term
clinical benefit in breast cancer: The CTNeoBC pooled analysis.
Lancet. 384:164–172. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Prowell TM and Pazdur R: Pathological
complete response and accelerated drug approval in early breast
cancer. N Engl J Med. 366:2438–2441. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Folkman J, Watson K, Ingber D and Hanahan
D: Induction of angiogenesis during the transition from hyperplasia
to neoplasia. Nature. 339:58–61. 1989. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gasparini G: Clinical significance of the
determination of angiogenesis in human breast cancer: Update of the
biological background and overview of the Vicenza studies. Eur J
Cancer. 32A:1–2493. 1996.
|
|
10
|
Uzzan B, Nicolas P, Cucherat M and Perret
GY: Microvessel density as a prognostic factor in women with breast
cancer: A systematic review of the literature and meta-analysis.
Cancer Res. 64:2941–2955. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Hampson IN, Hampson L, Kumar P,
Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling
of transforming growth factor beta1 on human vascular endothelial
cells. FASEB J. 14:55–64. 2000.PubMed/NCBI
|
|
12
|
Tanaka F, Otake Y, Yanagihara K, Kawano Y,
Miyahara R, Li M, Yamada T, Hanaoka N, Inui K and Wada H:
Evaluation of angiogenesis in non-small cell lung cancer:
Comparison between anti-CD34 antibody and anti-CD105 antibody. Clin
Cancer Res. 7:3410–3415. 2001.PubMed/NCBI
|
|
13
|
Schiff R, Massarweh SA, Shou J, Bharwani
L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor
and growth factor pathways as a molecular target for overcoming
endocrine resistance. Clin Cancer Res. 10 Suppl:331S–336S. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Berns K, Horlings HM, Hennessy BT,
Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM,
Stemke-Hale K, Hauptmann M, et al: A functional genetic approach
identifies the PI3K pathway as a major determinant of trastuzumab
resistance in breast cancer. Cancer Cell. 12:395–402. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Baselga J, Campone M, Piccart M, Burris HA
III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun
F, et al: Everolimus in postmenopausal hormone-receptor-positive
advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Andre F, O'Regan R, Ozguroglu M, Toi M, Xu
B, Jerusalem G, Masuda N, Wilks S, Arena F, Isaacs C, et al:
Everolimus for women with trastuzumab-resistant, HER2-positive,
advanced breast cancer (BOLERO-3): A randomised, double-blind,
placebo-controlled phase 3 trial. Lancet Oncol. 15:580–591. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Rau KM, Huang CC, Chiu TJ, Chen YY, Lu CC,
Liu CT, Pei SN and Wei YC: Neovascularization evaluated by CD105
correlates well with prognostic factors in breast cancers. Exp Ther
Med. 4:231–236. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Health Promotion Administration, Ministry
of Health and Welfare, Taiwan, . 2013, Taiwan Cancer Registry
annual report. Taiwan, Taipei: 2016, http://www.hpa.gov.tw/File/Attach/5191/File_6166.pdfJune
14–2017
|
|
20
|
American Joint Committee on Cancer, .
https://cancerstaging.org/references-tools/deskreferences/Pages/default.aspxSeptember
9–2017
|
|
21
|
Sorlie T, Perou CM, Tibshirani R, Aas T,
Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey
SS, et al: Gene expression patterns of breast carcinomas
distinguish tumor subclasses with clinical implications. Proc Natl
Acad Sci USA. 98:10869–10874. 2001; View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Berruti A, Brizzi MP, Generali D, Ardine
M, Dogliotti L, Bruzzi P and Bottini A: Presurgical systemic
treatment of nonmetastatic breast cancer: Facts and open questions.
Oncologist. 13:1137–1148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
von Minckwitz G, Untch M, Blohmer JU,
Costa SD, Eidtmann H, Fasching PA, Gerber B, Eiermann W, Hilfrich
J, Huober J, et al: Definition and impact of pathologic complete
response on prognosis after neoadjuvant chemotherapy in various
intrinsic breast cancer subtypes. J Clin Oncol. 30:1796–1804. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gianni L, Pienkowski T, Im YH, Roman L,
Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J,
Im SA, et al: Efficacy and safety of neoadjuvant pertuzumab and
trastuzumab in women with locally advanced, inflammatory, or early
HER2-positive breast cancer (NeoSphere): A randomised multicentre,
open-label, phase 2 trial. Lancet Oncol. 13:25–32. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liedtke C, Mazouni C, Hess KR, André F,
Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B,
Green M, et al: Response to neoadjuvant therapy and long-term
survival in patients with triple-negative breast cancer. J Clin
Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Schneider BP, Shen F and Miller KD:
Pharmacogenetic biomarkers for the prediction of response to
antiangiogenic treatment. Lancet Oncol. 13:e427–e436. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pang R and Poon RT: Angiogenesis and
antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett.
242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Webber K, Cooper A, Kleiven H, Yip D and
Goldstein D: Management of metastatic renal cell carcinoma in the
era of targeted therapies. Intern Med J. 41:594–605. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fakhrejahani E and Toi M: Antiangiogenesis
therapy for breast cancer: An update and perspectives from clinical
trials. Jpn J Clin Oncol. 44:197–207. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Burstein HJ, Chen YH, Parker LM, Savoie J,
Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, et al:
VEGF as a marker for outcome among advanced breast cancer patients
receiving anti-VEGF therapy with bevacizumab and vinorelbine
chemotherapy. Clin Cancer Res. 14:7871–7877. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kraby MR, Krüger K, Opdahl S, Vatten LJ,
Akslen LA and Boflin AM: Microvascular proliferation in luminal A
and basal-like breast cancer subtypes. J Clin Pathol. 68:891–897.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fox SB, Gasparini G and Harris AL:
Angiogenesis: Pathological, prognostic, and growth-factor pathways
and their link to trial design and anticancer drugs. Lancet Oncol.
2:278–289. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mineo TC, Ambrogi V, Baldi A, Rabitti C,
Bollero P, Vincenzi B and Tonini G: Prognostic impact of VEGF,
CD31, CD34, and CD105 expression and tumour vessel invasion after
radical surgery for IB-IIA non-small cell lung cancer. J Clin
Pathol. 57:591–537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miller DW, Graulich W, Karges B, Stahl S,
Ernst M, Ramaswamy A, Sedlacek HH, Müller R and Adamkiewicz J:
Elevated expression of endoglin, a component of the
TGF-beta-receptor complex, correlates with proliferation of tumor
endothelial cells. Int J Cancer. 81:568–572. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nassiri F, Cusimano MD, Scheithauer BW,
Rotondo F, Fazio A, Yousef GM, Syro LV, Kovacs K and Lloyd RV:
Endoglin (CD105): A review of its role in angiogenesis and tumor
diagnosis, progression and therapy. Anticancer Res. 31:2283–2290.
2011.PubMed/NCBI
|
|
37
|
Klijn JG, Berns EM and Foekens JA:
Prognostic factors and response to therapy in breast cancer. Cancer
Surv. 18:165–198. 1993.PubMed/NCBI
|
|
38
|
Systemic treatment of early breast cancer
by hormonal, cytotoxic, or immune therapy. 133 randomised trials
involving 31,000 recurrences and 24,000 deaths among 75,000 women.
Early Breast Cancer Trialists' Collaborative Group. Lancet.
339:71–85. 1992.PubMed/NCBI
|
|
39
|
Ciruelos Gil EM: Targeting the
PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
